AnaptysBio Inc

NASDAQ:ANAB   3:59:59 PM EDT
27.65
+1.92 (+7.46%)
Products, Regulatory

Anaptysbio Reports Positive Topline Data From Gallop Phase 2 Clinical Trial Of Imsidolimab In Moderate-To-Severe Generalized Pustular Psoriasis

Published: 10/13/2020 13:32 GMT
AnaptysBio Inc (ANAB) - Anaptysbio Reports Positive Topline Data From Gallop Phase 2 Clinical Trial of Imsidolimab in Moderate-to-severe Generalized Pustular Psoriasis (gpp).
Anaptysbio Reports Positive Topline Data From Gallop Phase 2 Clinical Trial of Imsidolimab in Moderate-to-severe Generalized Pustular Psoriasis (gpp).
Anaptysbio Inc - 6 of 8 Patients Achieved Primary Endpoint of Improvement in Clinical Global Impression Scale on Day 29.
Anaptysbio Inc - Rapid Reduction of Skin Pustules by 60% on Day 8 and 94% Clearance on Day 29.
Anaptysbio Inc - FDA End-of-phase 2 Meeting Anticipated in Q4 2020 to Outline Registration Path of Imsidolimab for Treatment of Gpp.
Anaptysbio Inc - Palmoplantar Pustulosis (ppp) Phase 2 Poplar Trial Enrollment Completed With Top-line Data Anticipated in Q1 2021.
Anaptysbio Inc - Initiation of Imsidolimab Phase 2 Trials in Egfr-mediated Skin Toxicity and Ichthyosis Anticipated in Q4 2020.
Anaptysbio Inc - Plans to Report Full Data From Gallop Trial at a Medical Conference in 2021.